Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly Helps Organize Education Program On Prevention Of Common Respiratory Infectious Disease

This article was originally published in PharmAsia News

Executive Summary

Eli Lilly and the committee on national care series activities recently kicked off an education program called "family medicine kit" that targets common respiratory infectious disease prevention in Beijing. The program will include educational activities in areas with a high prevalence of infectious disease by distributing free handbooks, posters and flyers and by starting a special column in the media. To be rolled out in three phases, the family medicine kit will be progressively launched in 40 major cities nationwide, directly benefiting more than 8 million people. Targeted mainly at the female population, the program will publicize knowledge of family health management, family drug safety, family nursing and first aid, common disease prevention and treatment, and respiratory infectious disease prevention. (Click here for more - Chinese Language)

You may also be interested in...



Cosmetic And Personal Care Trademark Review 20 October, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Novartis Takes Huntington's Path With SMA Therapy Branaplam

With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.

With $850m, Nuvation Aims To Speed Novel Cancer Drugs To Patients

Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.

UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel